Cargando…

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Detalles Bibliográficos
Autores principales: Ren, Daixi, Hua, Yuze, Yu, Boyao, Ye, Xin, He, Ziheng, Li, Chunwei, Wang, Jie, Mo, Yongzhen, Wei, Xiaoxu, Chen, Yunhua, Zhou, Yujuan, Liao, Qianjin, Wang, Hui, Xiang, Bo, Zhou, Ming, Li, Xiaoling, Li, Guiyuan, Li, Yong, Zeng, Zhaoyang, Xiong, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020589/
https://www.ncbi.nlm.nih.gov/pubmed/32059674
http://dx.doi.org/10.1186/s12943-020-01148-y
_version_ 1783497779890356224
author Ren, Daixi
Hua, Yuze
Yu, Boyao
Ye, Xin
He, Ziheng
Li, Chunwei
Wang, Jie
Mo, Yongzhen
Wei, Xiaoxu
Chen, Yunhua
Zhou, Yujuan
Liao, Qianjin
Wang, Hui
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Guiyuan
Li, Yong
Zeng, Zhaoyang
Xiong, Wei
author_facet Ren, Daixi
Hua, Yuze
Yu, Boyao
Ye, Xin
He, Ziheng
Li, Chunwei
Wang, Jie
Mo, Yongzhen
Wei, Xiaoxu
Chen, Yunhua
Zhou, Yujuan
Liao, Qianjin
Wang, Hui
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Guiyuan
Li, Yong
Zeng, Zhaoyang
Xiong, Wei
author_sort Ren, Daixi
collection PubMed
description
format Online
Article
Text
id pubmed-7020589
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70205892020-02-20 Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy Ren, Daixi Hua, Yuze Yu, Boyao Ye, Xin He, Ziheng Li, Chunwei Wang, Jie Mo, Yongzhen Wei, Xiaoxu Chen, Yunhua Zhou, Yujuan Liao, Qianjin Wang, Hui Xiang, Bo Zhou, Ming Li, Xiaoling Li, Guiyuan Li, Yong Zeng, Zhaoyang Xiong, Wei Mol Cancer Correction BioMed Central 2020-02-14 /pmc/articles/PMC7020589/ /pubmed/32059674 http://dx.doi.org/10.1186/s12943-020-01148-y Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Correction
Ren, Daixi
Hua, Yuze
Yu, Boyao
Ye, Xin
He, Ziheng
Li, Chunwei
Wang, Jie
Mo, Yongzhen
Wei, Xiaoxu
Chen, Yunhua
Zhou, Yujuan
Liao, Qianjin
Wang, Hui
Xiang, Bo
Zhou, Ming
Li, Xiaoling
Li, Guiyuan
Li, Yong
Zeng, Zhaoyang
Xiong, Wei
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title_full Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title_fullStr Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title_full_unstemmed Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title_short Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
title_sort correction to: predictive biomarkers and mechanisms underlying resistance to pd1/pd-l1 blockade cancer immunotherapy
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020589/
https://www.ncbi.nlm.nih.gov/pubmed/32059674
http://dx.doi.org/10.1186/s12943-020-01148-y
work_keys_str_mv AT rendaixi correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT huayuze correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT yuboyao correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT yexin correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT heziheng correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT lichunwei correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT wangjie correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT moyongzhen correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT weixiaoxu correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT chenyunhua correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT zhouyujuan correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT liaoqianjin correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT wanghui correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT xiangbo correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT zhouming correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT lixiaoling correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT liguiyuan correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT liyong correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT zengzhaoyang correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy
AT xiongwei correctiontopredictivebiomarkersandmechanismsunderlyingresistancetopd1pdl1blockadecancerimmunotherapy